Read by QxMD icon Read

breast cancer and lncRNA

Zejun Gao, Hai Wang, Hangyu Li, Min Li, Jia Wang, Wenwen Zhang, Xiubin Liang, Dongming Su, Jinhai Tang
Cancer susceptibility candidate 2 (CASC2), a long non-coding RNA (lncRNA), has been demonstrated to be a tumor suppressor in several types of cancer. However, the role and mechanism of CASC2 in breast cancer (BC) have not been investigated. In the present study, the expression and functions of CASC2 in BC were investigated. The expression of CASC2 was significantly decreased in BC tissues and cells compared with adjacent normal tissues and mammary epithelial cells, respectively. CASC2 overexpression inhibited the viability, migration and invasion, and elevated apoptosis of BC cells...
August 13, 2018: International Journal of Oncology
Haihua Wu, Yueyue Wang, Tiantian Chen, Yu Li, Haifeng Wang, Lingyu Zhang, Sulian Chen, Wenrui Wang, Changjie Chen, Qingling Yang
Accumulating evidence demonstrates that lncRNA SPRY4-IT1 plays a vital role in the development of breast cancer. However, the underlying mechanism has not been eventually illuminated. We aimed to explore the biological activity of lncRNA SPRY4-IT1 in breast cancer cells and whether NT21MP could exert its anti-tumor effect by regulating lncRNA SPRY4-IT1 and its target gene SKA2. Real-time RT-PCR, western blotting, wound healing assay, invasion assay, were used to achieve this goal. We found that lncRNA SPRY4-IT1 was highly expressed in breast cancer cells...
August 13, 2018: Bioscience Reports
Yiping Huang, Yingying Hu, Zujian Jin, Zhaojun Shen
BACKGROUND: The functionality of lncRNA snaR has only been characterized in breast cancer and colon cancer. The aim of the current study is to explore the involvement of lncRNA snaR in ovarian carcinoma (OC). MATERIALS AND METHODS: Expression of lncRNA snaR and GRB2-associated binding protein 2 (GAB2) in plasma of both patients with OC and healthy females was detected by qRT-PCR. Application value of plasma lncRNA snaR in the diagnosis of OC was evaluated by ROC analysis...
August 1, 2018: Biochemical and Biophysical Research Communications
Rana Ahmed Youness, Reem Amr Assal, Amira Abdel Motaal, Mohamed Zakaria Gad
Hydrogen sulphide (H2 S) gas has been recognized as an intracellular mediator influencing an array of signaling pathways. Yet, the role of H2 S in cancer progression has been controversial. This study aims to unravel the role of exogenous H2 S in triple negative breast cancer (TNBC) and to further investigate any possible association of H2 S mediated actions with the endogenous production of nitric oxide (NO) gas. A wide concentration range of NaHS (20-2000 μM) and a variable reaction time (2-72 h) were probed...
August 3, 2018: Nitric Oxide: Biology and Chemistry
Abbas Salavaty, Fatemeh Movahedi Motlagh, Mehri Barabadi, Hamid Cheshomi, Mohammad Javad Dehghan Esmatabadi, Mozhdeh Shahmoradi, Hamid Reza Soleimanpour-Lichaei
BACKGROUND: Long noncoding RNAs (lncRNAs) refer to a group of non-protein-coding RNAs that are usually more than 200 nucleotides. These long transcripts play significant roles in diverse cellular processes, mostly through epigenetic mechanisms. Thus, dysregulation of lncRNAs is associated with various diseases, especially cancer. This study aims to investigate the probable roles of RAB6C-AS1 lncRNA in different cancers. METHODS: Real-time quantitative reverse transcription-polymerase chain reaction was applied for the analysis of RAB6C-AS1 lncRNA amplification in gastric cancer (GC) samples compared with normal ones...
August 4, 2018: Journal of Cellular Physiology
Dongfeng Wang, Jian Li, Fengling Cai, Zhi Xu, Li Li, Huanfeng Zhu, Wei Liu, Qingyu Xu, Jian Cao, Jingfeng Sun, Jinhai Tang
Breast cancer is the most frequent malignant disease in women worldwide. It is a heterogeneous and complex genetic disease with different molecular characteristics. MAPT-AS1, a long non-coding RNA(lncRNA) existing at the anti-sense strand of MAPT (microtubule associated protein tau) promoter region, was believed to regulate MAPT which was associated with disease state in Parkinson's disease. But the role of MAPT-AS1 in breast cancer has never been reported. In our study we found that MAPT-AS1 is overexpressed in breast cancer but not in triple negative breast cancer(TNBC), and high expression of MAPT-AS1 was correlated with better patient survival...
August 3, 2018: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
Huaying Dong, Wei Wang, Shaowei Mo, Qiang Liu, Xin Chen, Ru Chen, Yu Zhang, Kejian Zou, Mulin Ye, Xionghui He, Fan Zhang, Jing Han, Jianguo Hu
Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become one major obstacle for improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behaviour can be modulated by long non-coding RNAs (lncRNAs), the contributions of lncRNAs in progression and trastuzumab resistance of breast cancer are largely unknown. To this end, the involvement and regulatory functions of lncRNA SNHG14 in human breast cancer were investigated. RT-qPCR assay showed that SNHG14 was up-regulated in breast cancer tissues and associated with trastuzumab response...
July 31, 2018: Journal of Cellular and Molecular Medicine
Jiezhi Ma, Min Xue
Introduction LINK-A lncRNA is a well-characterized oncogenic lncRNA only in triple negative breast cancer (TNBC). Our study was carried out to investigate the possible involvement of LINK-A lncRNA in ovarian carcinoma. Methods Expression of LINK-A in ovarian biopsies and plasma of both ovarian carcinoma patients and healthy females was detected by qRT-PCR. Plasma TGF-β1 was detected by ELISA. Correlation between plasma LINK-A and TGF-β1 was analyzed by Pearson correlation analysis. Correlation between plasma LINK-A and patients' clinicopathological data was analyzed by Chi-square test...
July 30, 2018: Bioscience Reports
Xiaojia Huang, Xinhua Xie, Peng Liu, Lu Yang, Bo Chen, Cailu Song, Hailin Tang, Xiaoming Xie
Long non-coding RNAs (lncRNAs) are reported to play vital roles in the progress of multiple cancers. However, the functions of lncRNAs in breast cancer remain to be discovered. We performed microarrays to identify the differentially expressed mRNAs and lncRNAs in breast tissues with or without miR-34a knockout. To explore the functions of the differentially expressed mRNA and lncRNA in breast cancer, we conducted a series of experiments. We found that Adam12 and lnc015192 were significantly upregulated in miR-34a knockout breast tissues...
July 24, 2018: Oncogene
Shaowei Wang, Hao Ke, Honglei Zhang, Yujie Ma, Lei Ao, Li Zou, Qin Yang, Hao Zhu, Jianyun Nie, Chunlian Wu, Baowei Jiao
Triple-negative breast cancer (TNBC) exhibits poor prognosis, with high metastasis and low survival. Long non-coding RNAs (lncRNAs) play critical roles in tumor progression. Here, we identified lncRNA MIR100HG as a pro-oncogene for TNBC progression. Knockdown of MIR100HG decreased cell proliferation and induced cell arrest in the G1 phase, whereas overexpression of MIR100HG significantly increased cell proliferation. Furthermore, MIR100HG regulated the p27 gene to control the cell cycle, and subsequently impacted the progression of TNBC...
July 24, 2018: Cell Death & Disease
Xin Liu, Tong Zhao, Xue Bai, Mingqi Li, Jingli Ren, Mengxue Wang, Ranchen Xu, Shuqian Zhang, Huimin Li, Yingying Hu, Liangjun Xie, Ying Zhang, Lida Yang, Chaoqi Yan, Yong Zhang
BACKGROUND/AIMS: Non-coding RNAs (ncRNAs) play vital regulatory roles in many tumors. However, the functional roles of these transcripts responsible for their dysregulation in breast cancer (BC) are not thoroughly understood. METHODS: We examined the expression of microRNA miR-1471 in BC specimens. Online analysis tools predicted that lncRNA LOC101930370 might act as an endogenous 'sponge' by competing for miR-1471 binding targets. Luciferase assays were used to prove the interaction of LOC101930370, miR-1471 and SHH...
July 24, 2018: Cellular Physiology and Biochemistry
Fei Xing, Yin Liu, Shih-Ying Wu, Kerui Wu, Sambad Sharma, Yin-Yuan Mo, Jiamei Feng, Stephanie Sanders, Guangxu Jin, Ravi Singh, Pierre-Alexandre Vidi, Abhishek Tyagi, Michael D Chan, Jimmy Ruiz, Waldemar Debinski, Boris C Pasche, Hui-Wen Lo, Linda J Metheny-Barlow, Ralph B D'Agostino, Kounosuke Watabe
Up to 30% of patients with metastatic breast cancer eventually develop brain metastasis, yet the pathologic mechanism behind this development remains poorly understood. Here, we profiled long noncoding RNAs in brain metastatic tumors from patients with breast cancer and found that the X-inactive-specific transcript (XIST) was significantly downregulated in these tissues. XIST expression levels inversely correlated with brain metastasis, but not with bone metastasis in patients. Silencing of XIST preferentially promoted brain metastatic growth of XISThigh cells in our xenograft models...
August 1, 2018: Cancer Research
Huaying Dong, Wei Wang, Ru Chen, Yu Zhang, Kejian Zou, Mulin Ye, Xionghui He, Fan Zhang, Jing Han
Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become an important obstacle to improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behavior may be modulated by long non‑coding RNAs (lncRNAs), the contributions of lncRNAs within extracellular vesicles (exosomes) are largely unknown. To this end, the involvement and regulatory functions of potential lncRNAs contained within exosomes during the formation of chemoresistance in human breast cancer were investigated...
September 2018: International Journal of Oncology
Juan Gu, Yueping Wang, Xuedong Wang, Daoping Zhou, Xinguo Wang, Ming Zhou, Zhimin He
BACKGROUND/AIMS: An increasing body of evidence shows that long noncoding RNAs (lncRNAs) are involved in many different cancers. In this study, we aimed to investigate the competing endogenous RNA (ceRNA)-dependent mechanism by which the lncRNA GAS5 contributes to the development of breast cancer. METHODS: A total of 68 breast cancer patients were enrolled, and breast cancer and adjacent normal tissues were collected. The human breast cancer cell lines MDA-MB-231, MDA-MB-453, BT549, SK-BR-3 and MCF-7 and human breast cell line MCF10A were utilized in this study...
July 13, 2018: Cellular Physiology and Biochemistry
Liyun Luo, Hailin Tang, Li Ling, Nan Li, Xiaoting Jia, Zhijie Zhang, Xiaorong Wang, Lejuan Shi, Jiang Yin, Ni Qiu, Hao Liu, Ying Song, Kai Luo, Hongsheng Li, Zhimin He, Guopei Zheng, Xiaoming Xie
Breast cancer is a heterogeneous disease, and triple-negative breast cancer (TNBC) continues to be a serious health problem. The potential involvement of lncRNAs in TNBC progression remains unexplored. Here, we demonstrated that LINC01638 is highly expressed in TNBC tissues and cells. LINC01638 maintains the mesenchymal traits of TNBC cells, including an enriched epithelial-mesenchymal transition (EMT) signature and cancer stem cell-like state. LINC01638 knockdown suppresses tumor proliferation and metastasis both in vitro and in vivo...
July 12, 2018: Oncogene
Cheng-Wei Lu, Dan-Dan Zhou, Tian Xie, Ji-Long Hao, Om Prakash Pant, Cheng-Bo Lu, Xiu-Fen Liu
The cancers are the leading cause of disease-related deaths worldwide with a high risk of morbidity and mortality. Long noncoding RNAs (lncRNAs) play a critical role in a wide range of biological processes, including tumorigenesis. HOXA11-AS (NCRNA00076), the antisense strands of HOXA11 gene, was initially revealed in a mouse embryonic cDNA library in 2009 and it was a fairly novel lncRNA. This review summarized the advanced research progression concerning the expression and role of HOXA11-AS in different human malignancies...
July 10, 2018: Cancer Medicine
Meiyu Dai, Shan Li, Xue Qin
Colorectal neoplasia differentially expressed (CRNDE), as a long noncoding RNA (lncRNA), has attracted increasing attention in recent years and has been documented to be at abnormally high expression in various types of cancer, such as colorectal cancer, glioma, hepatocellular carcinoma, lung cancer, and breast cancer. It could not only be used as a clinical biomarker for the early diagnosis and prognosis evaluation in a variety of cancers but also promote the development and progress of various tumor cells...
2018: OncoTargets and Therapy
Rubén Rodríguez Bautista, Alette Ortega Gómez, Alfredo Hidalgo Miranda, Alejandro Zentella Dehesa, Cynthia Villarreal-Garza, Federico Ávila-Moreno, Oscar Arrieta
Triple-negative breast cancer (TNBC) has been clinically difficult to manage because of tumor aggressiveness, cellular and histological heterogeneity, and molecular mechanisms' complexity. All this in turn leads us to evaluate that tumor biological behavior is not yet fully understood. Additionally, the heterogeneity of tumor cells represents a great biomedicine challenge in terms of the complex molecular-genetical-transcriptional and epigenetical-mechanisms, which have not been fully elucidated on human solid tumors...
2018: Clinical Epigenetics
Rong Liu, Rong Hu, Wei Zhang, Hong-Hao Zhou
AIM: We aimed to develop a long noncoding RNA (lncRNA) expression signature that can predict response to tamoxifen. MATERIALS & METHODS: LncRNA expression profiling was mined in two cohorts from Gene Expression Omnibus (GSE6532, GSE9195, n = 412). RESULTS: A set of lncRNAs (LINC01191, RP4-639F20.1 and CTC-429P9.3) associated with distant metastasis-free survival was established. Estrogen receptor-positive breast cancer patients in the training series could be classified into high- and low-risk groups with significantly different distant metastasis-free survival values based on this signature (hazard ratio [HR]: 5...
July 9, 2018: Pharmacogenomics
Jicai Wang, Zhilei Su, Shounan Lu, Wen Fu, Zhifa Liu, Xingming Jiang, Sheng Tai
Long non-coding RNAs (lncRNAs), a novel class of noncoding RNAs, are commonly defined as RNA molecules more than 200 nucleotides in length. Emerging research indicated that lncRNA played a vital role in human tumorigenesis and progression by serving as tumor oncogenes or suppressors. LncRNA has been shown to get involved in participate various biological processes, such as cell growth, anti-apoptosis, migration and invasion. LncRNA HOXA cluster antisense RNA2 (HOXA-AS2) is a novel cancer-related lncRNA. It was recently found to exhibit aberrant expression in a variety of malignancies, including breast cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma and pancreatic cancer...
July 4, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"